Loading...
01/09 23:14
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary presents a mixed picture. Financial performance shows improvement in gross margins and operating losses, but revenue declined, raising concerns. Product development and market strategy are positive, with new partnerships and client growth. However, cash flow breakeven delay and lack of specific guidance in Q&A dampen optimism. Shareholder returns weren't discussed. Overall, the sentiment is neutral, reflecting balanced positive and negative factors.
Revenue $5 million, which was lower year-over-year and quarter-over-quarter. The decline reflects the non-renewal of a large scope of work with a national health plan in early 2025 and a deliberate shift from one-time revenue streams towards long-term annual recurring revenue.
GAAP Gross Margin 60%, up from 55% in Q2 2025 and 52% in Q3 2024. This improvement is attributed to the benefits of a software-led model and disciplined cost management.
Non-GAAP Gross Margin (B2B2C) Above 80% for seven consecutive quarters since the beginning of 2024, reflecting the benefits of a software-first model.
Operating Expenses Reduced by $17.2 million or 31% in the first 9 months of 2025, and by $3.4 million or 21% during Q3 2025 compared to the year-ago period. This reduction was driven by post-merger integration, process automation, organizational streamlining, and expanded use of AI-based workflows.
Operating Loss Improved by $18 million or 39% for the 9-month period compared to the previous year.
Cash and Equivalents $31.9 million as of September 30, 2025, reflecting a $17.5 million private placement of common stock and equivalents.
Multi-condition digital health platform: DarioHealth's platform integrates physical, mental, and behavioral care, addressing conditions like diabetes, hypertension, weight management, musculoskeletal pain, and mental health. Over 50% of new clients in 2025 chose this solution.
AI-powered personalized engine: The platform uses AI to combine biometric, self-reported, and behavioral data, delivering measurable outcomes and driving high gross margins (60% GAAP, 80%+ non-GAAP).
New product partnerships: Dario integrated OneStep's AI-powered fall risk assessment technology, enhancing ROI for health plans by reducing avoidable claims and improving safety.
Client base expansion: Dario now serves over 125 clients, including 4 national and 7 major regional health plans, and numerous Fortune-level employers, reaching over 116 million covered lives.
New health plan launches: UnitedHealthcare launched Dario on its digital marketplace, with a full national rollout planned for January 2026. Premera Blue Cross and Florida Blue also launched Dario through partnerships.
Public sector opportunities: Dario is exploring federal and state-funded health programs, leveraging its pricing and clinical benefits to compete in this space.
Revenue model transition: Shifted from one-time revenue streams to high-margin annual recurring revenue, targeting $12.4 million in new business for 2026.
Cost reductions: Reduced operating expenses by $17.2 million (31%) in the first 9 months of 2025, with further reductions expected.
Financial position: Completed a $17.5 million private placement, simplified capital structure, and improved operating loss by $18 million (39%) year-over-year.
Channel partnerships: Strengthened partnerships with Solera Health, Aetna, and Amwell, expanding market access and accelerating deal closures.
Pharma services growth: Transitioned to a recurring revenue model, focusing on therapeutic areas like MASH, delivering significant ROI for pharma clients.
Special committee engagement: Dario engaged Perella Weinberg Partners to explore strategic opportunities following unsolicited expressions of interest.
Revenue Decline: Revenue for the third quarter of 2025 was $5 million, down from $7.4 million in the third quarter of 2024. This decline reflects the non-renewal of a large scope of work with a national health plan in early 2025 and the shift from one-time revenue streams to long-term recurring revenue.
Client Retention Risk: The company has set an internal benchmark to retain roughly 85% of its clients year-over-year, but achieving this target is critical to maintaining revenue stability.
Pipeline Conversion Uncertainty: The company is targeting $12.4 million in new business for 2026, but a portion of this is still in late-stage development, creating uncertainty in achieving these targets.
Economic and Market Conditions: Policy tailwinds and rising healthcare costs are driving demand for digital health solutions, but economic uncertainties could impact client budgets and adoption rates.
Operational Efficiency Challenges: While operating expenses have been reduced significantly, further reductions of 10%-15% are planned, which may strain resources and impact operational capabilities.
Regulatory and Competitive Pressures: The company operates in a highly regulated and competitive digital health market, which could impact its ability to scale and maintain margins.
Dependence on Channel Partners: Over 80% of new logo wins come from channel partners, creating dependency on these relationships for growth and market access.
Capital Structure and Financial Resilience: The company has simplified its capital structure and raised $17.5 million, but financial resilience remains critical as it aims for cash flow breakeven by late 2026 to early 2027.
Revenue expectations: The company is targeting $12.4 million in new business for implementation in 2026, including committed annual recurring revenues and late-stage pipeline opportunities nearing completion. Revenue momentum is expected to grow in 2026, supported by new accounts and a $69 million pipeline.
Profitability and cash flow: DarioHealth expects to reach cash flow breakeven by late 2026 to early 2027. Operating expenses are projected to decline by an additional 10% to 15% over the next 12 to 15 months, contributing to profitability.
Market trends and business segment performance: The company anticipates strong demand for its multi-condition digital health platform, with a growing preference for integrated solutions among employers and health plans. The average employer account size has nearly doubled compared to the previous year, and the company is seeing significant traction in the public sector and pharma business.
Client and account growth: DarioHealth has signed 45 new accounts year-to-date in 2025, surpassing its goal of 40. The company expects continued client growth, with several large health plans and employers onboarding in 2026. Client retention remains strong at 90%.
Strategic partnerships and launches: Key partnerships include UnitedHealthcare, Premera Blue Cross, Aetna, and Florida Blue, with major launches planned for 2026. These partnerships are expected to expand market access and accelerate growth.
Operational efficiency: The company has reduced operating expenses by $17.2 million (31%) in the first nine months of 2025 and plans further reductions through automation and AI-based workflows.
The selected topic was not discussed during the call.
The earnings call summary presents a mixed picture. Financial performance shows improvement in gross margins and operating losses, but revenue declined, raising concerns. Product development and market strategy are positive, with new partnerships and client growth. However, cash flow breakeven delay and lack of specific guidance in Q&A dampen optimism. Shareholder returns weren't discussed. Overall, the sentiment is neutral, reflecting balanced positive and negative factors.
The earnings call reveals several concerning factors: a 14.3% revenue decline, delayed cash flow breakeven, and client onboarding issues. Despite cost reductions and improved gross margins, the strategic shift to a SaaS model and competitive pressures pose risks. Q&A highlights management's unclear responses on financial impacts, further contributing to uncertainty. These factors suggest a negative sentiment, likely impacting the stock price negatively in the short term.
The earnings call presented a mixed picture. Financial performance showed improvement in revenue and reduced operating expenses, but the EPS miss and tariff-related delays are concerning. The Q&A highlighted uncertainties, especially regarding pharma contracts and health plan transitions. Positive aspects include new partnerships and client growth, but the lack of a share buyback program and competitive pressures are negatives. Overall, the sentiment is neutral, as positive developments are balanced by risks and uncertainties.
The earnings call highlights strong financial performance with a 17% revenue increase and improved margins. The acquisition of Twill and new pharma partnerships, along with a focus on cash flow breakeven, are positive indicators. Despite some tariff-related delays, the overall sentiment is positive with high client renewal rates and strategic growth plans. The market cap is unavailable, but the company's strategic initiatives and financial health suggest a likely positive stock price movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
